SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

All patients had received at least 2 prior lines of systemic cancer ... assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities.

The downregulation of ADH4 expression induces hepatocyte apoptosis, thereby contributing to liver fibrosis and the initiation of hepatocellular carcinoma (HCC). Moreover, sustained suppression of ...

This is the highest reported objective response rate of any systemic treatment in unresectable hepatocellular carcinoma, surpassing atezolizumab–bevacizumab (30%) 11 and STRIDE (20%). 13 However, this ...

LIVER cancer is the fourth most ... and advanced (Stage C) cases, treatment options may include regional chemotherapy, sometimes combined with systemic immunotherapy, or systemic immunotherapy ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

Italy New molecules/receptors/signaling pathways need to be identified as targets for the generation of new drugs for hepatocellular carcinoma (HCC) therapy. HCCs can be classified into subgroups ...

Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...